Watch SLDB. Know when insiders buy.
One email the day a filing lands. Free.
SLDB
Solid Biosciences Inc.
7.28
−0.01 −0.07%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · shorts 54
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $781.1MP/E —DIV YIELD —FCF YIELD -24.04%REV TTM —NET INCOME −$207.1MNET CASH —52W 3.93 – 11.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$57.4M | −$54.8M | — | -0.38 | −$52.6M | $150K | −$52.7M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$57.3M | −$56.7M | — | -0.52 | −$47.2M | $165K | −$47.4M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$49.4M | −$49.8M | — | -0.53 | −$53.6M | $565K | −$54.1M | Mar 19 |
| Q3 2025 · Sep 30 | — | — | — | −$48.1M | −$45.8M | — | -0.48 | −$33.5M | $85K | −$33.6M | Nov 3 |
| Q2 2025 · Jun 30 | — | — | — | −$41.7M | −$39.5M | — | -0.42 | −$37.4M | $377K | −$37.8M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$40.1M | −$39.3M | — | -0.59 | −$31.9M | $126K | −$32M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$39.9M | −$42.6M | — | -1.02 | −$29.6M | $204K | −$29.8M | Mar 19 |
| Q3 2024 · Sep 30 | — | — | — | −$35.2M | −$32.7M | — | -0.79 | −$23.7M | $15K | −$23.7M | Nov 3 |
| Q2 2024 · Jun 30 | — | — | — | −$27.8M | −$25.1M | — | -0.61 | −$21.5M | $286K | −$21.8M | Nov 3 |
| Q1 2024 · Mar 31 | — | — | — | −$26.9M | −$24.3M | — | -0.64 | −$25.2M | $149K | −$25.3M | Nov 3 |
| Q4 2023 · Dec 31derived | — | — | — | −$22.3M | −$20.3M | — | -1.00 | −$20.8M | $90K | −$20.9M | Mar 6 |
| Q3 2023 · Sep 30 | — | — | — | −$23.1M | −$21M | — | -1.05 | −$17.9M | $383K | −$18.3M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$179.2M | −$174.3M | — | -1.99 | −$156.3M | $1.2M | −$157.4M | — | — |
| FY2024 · to Dec 31 | — | — | −$129.7M | −$124.7M | — | -3.06 | −$100M | $654K | −$100.7M | — | — |
| FY2023 · to Dec 31 | — | — | −$104.3M | −$96M | — | -4.83 | −$94.2M | $1.5M | −$95.7M | — | — |
| FY2022 · to Dec 31 | $8.1M | — | −$106.5M | −$86M | -1062.3% | -10.10 | −$98M | $3M | −$101M | — | — |
| FY2021 · to Dec 31 | $13.6M | — | −$72.3M | −$72.2M | -530.0% | -10.14 | −$77.8M | $1.3M | −$79M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$88.4M | −$88.3M | — | -25.50 | −$56.6M | $899K | −$57.5M | — | — |
Every number comes from Solid Biosciences Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.